Single User License
INR 170925
Site License
INR 341850
Corporate User License
INR 512775

Service Tax Additional

select a format
Price

Single User License
USD 2500
Site License
USD 5000
Corporate User License
USD 7500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Global Clinical Trials Review, H1, 2015

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Global Clinical Trials Review, H1, 2015


  Request for Sample Report

Executive Summary

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Global Clinical Trials Review, H1, 2015

GlobalData's clinical trial report, "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Global Clinical Trials Review, H1, 2015" provides data on the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each

Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type

Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons To Buy

Understand the dynamics of a particular indication in a condensed manner

Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more

Obtain discontinued trial listing for trials across the globe

Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) 6

Report Guidance 6

Clinical Trials by Region 7

Clinical Trials and Average Enrollment by Country 8

Top Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Top Countries Contributing to Clinical Trials in Middle East and Africa 13

Top Countries Contributing to Clinical Trials in Central and South America 14

Clinical Trials by G7 Countries: Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) to Metabolic Disorders Clinical Trials 15

Clinical Trials by Phase in G7 Countries 16

Clinical Trials in G7 Countries by Trial Status 17

Clinical Trials by E7 Countries: Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) to Metabolic Disorders Clinical Trials 18

Clinical Trials by Phase in E7 Countries 19

Clinical Trials by Phase 20

In Progress Trials by Phase 21

Clinical Trials by Trial Status 22

Clinical Trials by End Point Status 23

Unaccomplished Trials of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) 24

Subjects Recruited Over a Period of Time 25

Clinical Trials by Sponsor Type 26

Prominent Sponsors 27

Top Companies Participating in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials 28

Prominent Drugs 29

Clinical Trial Profiles 30

Clinical Trial Overview of Top Companies 30

Sanofi 30

Clinical Trial Overview of Sanofi 30

Nuo Therapeutics, Inc. 31

Clinical Trial Overview of Nuo Therapeutics, Inc. 31

ZonMw 32

Clinical Trial Overview of ZonMw 32

PTC Therapeutics, Inc. 33

Clinical Trial Overview of PTC Therapeutics, Inc. 33

Parkway Pantai Limited 34

Clinical Trial Overview of Parkway Pantai Limited 34

Multiplex Pharma Holdings LLC 35

Clinical Trial Overview of Multiplex Pharma Holdings LLC 35

Fate Therapeutics, Inc. 36

Clinical Trial Overview of Fate Therapeutics, Inc. 36

ArmaGen Technologies, Inc. 37

Clinical Trial Overview of ArmaGen Technologies, Inc. 37

Clinical Trial Overview of Top Institutes / Government 38

Masonic Cancer Center 38

Clinical Trial Overview of Masonic Cancer Center 38

Los Angeles Biomedical Research Institute 39

Clinical Trial Overview of Los Angeles Biomedical Research Institute 39

University of California, Los Angeles 40

Clinical Trial Overview of University of California, Los Angeles 40

Erasmus MC 41

Clinical Trial Overview of Erasmus MC 41

University of Texas Southwestern Medical Center at Dallas 42

Clinical Trial Overview of University of Texas Southwestern Medical Center at Dallas 42

University of Chicago 43

Clinical Trial Overview of University of Chicago 43

University Hospital Hamburg-Eppendorf 44

Clinical Trial Overview of University Hospital Hamburg-Eppendorf 44

University of Louisville 45

Clinical Trial Overview of University of Louisville 45

Emory University 46

Clinical Trial Overview of Emory University 46

University of Minnesota 47

Clinical Trial Overview of University of Minnesota 47

Five Key Clinical Profiles 48

Appendix 81

Abbreviations 81

Definitions 81

Research Methodology 82

Secondary Research 82

About GlobalData 83

Contact Us 83

Disclaimer 83

Source 83

List of Figures

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials by Region (%), 2015* 7

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12

Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2015* 15

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17

Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2015* 18

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials by Phase (%), 2015* 20

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 21

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 22

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 23

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 25

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 26

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 27

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 28

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 29

GlobalData Methodology 82

List of Tables

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials by Region, 2015* 7

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 10

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, North America, Top Countries, 2015* 12

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14

Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2015* 15

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17

Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2015* 18

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials by Phase, 2015* 20

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 21

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 22

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 23

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Terminated Clinical Trials, 2015* 24

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 25

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 26

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 27

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 28

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 29

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2015* 30

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Nuo Therapeutics, Inc., 2015* 31

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by ZonMw, 2015* 32

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by PTC Therapeutics, Inc., 2015* 33

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Parkway Pantai Limited, 2015* 34

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Multiplex Pharma Holdings LLC, 2015* 35

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fate Therapeutics, Inc., 2015* 36

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by ArmaGen Technologies, Inc., 2015* 37

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Masonic Cancer Center, 2015* 38

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Los Angeles Biomedical Research Institute, 2015* 39

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, Los Angeles, 2015* 40

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Erasmus MC, 2015* 41

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Texas Southwestern Medical Center at Dallas, 2015* 42

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Chicago, 2015* 43

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospital Hamburg-Eppendorf, 2015* 44

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Louisville, 2015* 45

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Emory University, 2015* 46

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Minnesota, 2015* 47

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Clinical Trials, Trial Designs, Subjects Recruited, Unaccomplished Trials of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome), Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas, M.D. Andersons, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, National Cancer Center, University of Pennsylvania.


Related Products in vertical
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com